The U.S. mRNA synthesis raw materials market size was exhibited at USD 842.15 million in 2023 and is projected to hit around USD 1,125.20 million by 2033, growing at a CAGR of 2.94% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 866.91 Million |
Market Size by 2033 | USD 1,125.20 Million |
Growth Rate From 2024 to 2033 | CAGR of 2.94% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Type, Application, End-use |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | U.S. |
Key Companies Profiled | F. Hoffmann-La Roche Ltd.; Jena Bioscience GmbH; Merck KGaA; Yeasen Biotechnology (Shanghai) Co., Ltd.; BOC Sciences; Thermo Fisher Scientific, Inc.; Maravai LifeSciences; New England Biolabs; Creative Biogene; HONGENE; Evonik Industries AG |
This is attributed to the growing academic & industrial interest in mRNA technology, increasing funding for mRNA research, and raising awareness of the advantages of mRNA-based vaccines. Moreover, the increasing therapeutic applications of RNA technology are anticipated to provide significant demand for mRNA synthesis raw materials over the forecast period.
The COVID-19 pandemic has spurred the rapid adoption of mRNA technology, mainly through mRNA vaccines. Government agencies, research institutions, and pharmaceutical companies are prioritizing the development of efficient COVID-19 detection methods. mRNA vaccines, represented by mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases (NIAID) and Moderna, Inc., have proven highly effective, receiving emergency use authorization from the U.S. FDA in December 2020. This has led to a significant increase in mRNA vaccine usage during the pandemic.
Moreover, RNA centers have been established at numerous institutions to promote therapeutic uses for RNA, particularly In Vitro Transcribed (IVT) mRNA. These facilities include the Yale Center for RNA Science and Medicine, the RNA Institute at the University at Albany, the State University of New York, and the RNA Therapeutic Institute at the University of Massachusetts in the U.S. In addition, university spin-off businesses funded by significant venture capital infusions (such as Argos Medicines, Factor Bioscience, CureVac, Ethris, BioNTech, Moderna, eTheRNA, and Onkaido) have advanced the preclinical and clinical development of mRNA-based therapeutics.
Furthermore, mRNA vaccines direct the cells to produce proteins, driving the demand for mRNA-based vaccines due to the growing awareness among individuals. This, in turn, increases the demand for and surges in adopting mRNA vaccines among patient populations and biotech companies. For instance, in March 2022, a Phase 1 clinical trial was initiated by The National Institutes of Health's NIAID to evaluate three potential HIV vaccines using an mRNA platform.
Capping agents held the largest revenue market share of 41.02% in 2023 and is expected to grow at the highest CAGR over the forecast period. Capping and tailing are crucial stages in the development of mRNA for use in functional studies. These procedures reduce the translational difficulty and avoid degradation in eukaryotes. Capping agents act as binding molecules or stabilizers to prevent steric hindrance or aggregation. For instance, in September 2022, TriLink BioTechnologies, a manufacturer of raw materials, expanded its GMP-grade product line by offering N1-Methyl-Pseudouridine-5’-Triphosphate (N1meΨTP), an improved Nucleoside-Triphosphate (NTP) necessary for mRNA production. Thus, the increase in the development and launch of novel raw materials to be used in mRNA synthesis is expected to drive market growth.
The nucleotide segment is expected to register a significant CAGR over the forecast period. Nucleotide analogs with unique characteristics would be used as powerful drugs like mRNA-based therapeutics to fight a variety of pathogens or cellular probes. Thus, increasing use of nucleotides in mRNA therapies and drug discovery propelled the market growth.
Biopharmaceutical & pharmaceutical companies dominated the segment with a market share of 49.65% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. This is attributed to the increasing demand for the development of new therapeutics due to significant expansions in the pharmaceutical industry pipeline. For instance, according to a study published by Informa in April 2022, there were 46 drugs in the pipeline from Moderna, followed by 29 from BioNTech, 19 from CureVac, 11 from Sanofi, 10 from Pfizer, 5 and 4 from GSK and AstraZeneca, respectively.
The CROs & CMOs segment is expected to grow at a significant CAGR over the forecast period. This fast growth is due to vaccine developers entering into strategic agreements with contract service providers to meet the urgent global demand for mRNA-based vaccines, which led to a sharp increase in the outsourcing industry. In addition, some of the leading outsourcing companies are increasing their finances to strengthen their mRNA synthesis infrastructure and support segment growth. For instance, in June 2022, Vernal Biosciences finished its USD 21 million financing to incorporate its mRNA manufacturing solutions completely.
Vaccine production dominated the segment with a revenue market share of 83.86% in 2023 and is anticipated to grow at the highest CAGR over the forecast period. This is attributed to the high demand for mRNA vaccines during the COVID-19 pandemic and increased research on mRNA vaccine candidates for several diseases. Moreover, robust product pipelines and a rise in research activities are also supplementing market growth.
The therapeutics segment is expected to grow at a significant CAGR over the forecast period. Rising expenditures by key market players for the production of novel and effective mRNA therapeutics are expected to boost market growth over the forecast years. Moreover, the development and production of mRNA for therapeutic applications are relatively easy, scalable, and incredibly rapid. Due to this, the demand to produce mRNA therapeutics to combat future pandemics has increased gradually over the forecast years.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the U.S. mRNA synthesis raw materials market
Type
Application
End-use
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Type Segment
1.1.2. Application Segment
1.1.3. End-use Segment
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Primary Research
1.5. Information or Data Analysis:
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objective
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. mRNA Synthesis Raw Material Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing academic & industrial interest in mRNA technology
3.2.1.2. Advantages of mRNA vaccines
3.2.1.3. Increasing funding for mRNA research
3.2.2. Market Restraint Analysis
3.2.2.1. Nonexistence of effective government regulations for mRNA-based product approvals
3.2.2.2. High cost of mRNA synthesis raw materials
3.2.3. Market Challenge Analysis
3.2.3.1. Lack of long-lasting and affordable manufacturing processes
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. U.S. mRNA Synthesis Raw Material Market: Type Estimates & Trend Analysis
4.1. Type Segment Dashboard
4.2. U.S. mRNA Synthesis Raw Materials Market Type Movement Analysis
4.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Type, 2021 to 2033 (USD Million)
4.4. Capping Agents
4.4.1. Capping Agents Market Estimates and Forecasts, 2021 - 2033
4.5. Nucleotides
4.5.1. Nucleotides Market Estimates and Forecasts, 2021 - 2033
4.6. Plasmid DNA
4.6.1. Plasmid DNA Market Estimates and Forecasts, 2021 - 2033
4.7. Enzymes
4.7.1. Enzymes Market Estimates and Forecasts, 2021 - 2033
4.7.2. Polymerase
4.7.2.1. Polymerase Market Estimates and Forecasts, 2021 - 2033
4.7.3. RNase Inhibitor
4.7.3.1. RNase Inhibitor Market Estimates and Forecasts, 2021 - 2033
4.7.4. DNase
4.7.4.1. DNase Market Estimates and Forecasts, 2021 - 2033
4.7.5. Others
4.7.5.1. Others Market Estimates and Forecasts, 2021 - 2033
4.8. Others
4.8.1. Others Market Estimates and Forecasts, 2021 - 2033
Chapter 5. U.S. mRNA Synthesis Raw Material Market: Application Estimates & Trend Analysis
5.1. Application Segment Dashboard
5.2. U.S. mRNA Synthesis Raw Materials Market Application Movement Analysis
5.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Vaccine Production
5.4.1. Vaccine Production Market Estimates and Forecasts, 2021 - 2033
5.5. Therapeutics Production
5.5.1. Therapeutics Production Market Estimates and Forecasts, 2021 - 2033
5.6. Others
5.6.1. Others Market Estimates and Forecasts, 2021 - 2033
Chapter 6. U.S. mRNA Synthesis Raw Material Market: End-use Estimates & Trend Analysis
6.1. End-use Segment Dashboard
6.2. U.S. mRNA Synthesis Raw Materials Market End-use Movement Analysis
6.3. U.S. mRNA Synthesis Raw Materials Market Size & Trend Analysis, by End-use, 2021 to 2033 (USD Million)
6.4. Biopharmaceutical & Pharmaceutical Companies
6.4.1. Biopharmaceutical & Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033
6.5. CROs & CMOs
6.5.1. CROs & CMOs Market Estimates and Forecasts, 2021 - 2033
6.6. Academic & Research Institutes
6.6.1. Academic & Research Institutes Market Estimates and Forecasts, 2021 - 2033
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2023
7.4. Company Profiles/Listing
7.4.1. F. Hoffmann-La Roche Ltd.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. Jena Bioscience GmbH
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Merck KGaA
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Yeasen Biotechnology (Shanghai) Co., Ltd
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. BOC Sciences
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. Thermo Fisher Scientific, Inc.
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. Maravai LifeSciences
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. New England Biolabs
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. Creative Biogene
7.4.9.1. Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. HONGENE
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives
7.4.11. Evonik Industries AG
7.4.11.1. Overview
7.4.11.2. Financial Performance
7.4.11.3. Product Benchmarking
7.4.11.4. Strategic Initiatives
7.4.12. GENEVANT SCIENCES CORPORATION
7.4.12.1. Overview
7.4.12.2. Financial Performance
7.4.12.3. Product Benchmarking
7.4.12.4. Strategic Initiatives